Product information and disease descriptionProduct descriptionProduct information
Dosing and administration
11 evidence topics · 8 sources
AXPAXLI (axitinib intravitreal implant)
Neovascular age-related macular degeneration
- Manufacturer
- Ocular Therapeutix
- Regulatory submission
- NDA planned for the fourth quarter of 2026
- Launch
- Anticipated in 2027
- Last updated